Between 2013 and 2023, the import value of pharmaceutical goods to China witnessed notable growth, increasing from $502.67 million in 2013 to $881.2 million in 2023. Key periods of growth include the significant increase in 2021 by 15.14%, while 2022 experienced a slight decline of 5.11%. The compound annual growth rate (CAGR) over the last five years (2018-2023) stands at 4.04%. For 2024 and beyond, a more modest growth is projected with a 5-year forecast CAGR of 2.65%, leading to a total import value of $1,049.7 million by 2028, representing a 13.97% growth by then.

Future trends to watch for:

Potential policy changes affecting import regulations and trade agreements between China and pharmaceutical-exporting countries.
Technological advancements in pharmaceutical manufacturing driving shifts in the global supply chain.
Potential changes in China's domestic pharmaceutical capabilities impacting import demands.
Market dynamics influenced by evolving healthcare needs and demographic changes in China.